Denecimig every-2-weeks dosing holds up in 26-week FRONTIER4 hemophilia A interim look
An interim analysis of 37 patients found no new safety signal and a 0.38 annualized bleed rate on the every-2-week dosing arm of Novo Nordisk's Phase 3 FRONTIER4 extension study.
Executive Summary
- An interim analysis from a Phase 3 open-label extension study looked at how patients with hemophilia A tolerated a less frequent, every-2-week dosing schedule of denecimig after switching over from earlier studies of the drug.
- Adverse events were mostly mild, none led to stopping treatment, and most patients had no treated bleeding episodes during the analysis period.
- The finding extends denecimig's established bleed-reduction profile, already shown in a separate Phase 3 trial published in the New England Journal of Medicine, to a less frequent injection interval.
- The analysis covers a small group of patients drawn from an ongoing extension study, so it reads as supportive rather than definitive on long-term tolerability at this dosing frequency.
The finding
Denecimig (Mim8) is a bispecific antibody designed to mimic the activity of clotting factor VIII, given by injection under the skin as prophylaxis against bleeding in hemophilia A, with or without factor VIII inhibitors. The FRONTIER4 study (NCT05685238) is an open-label extension that follows patients who had already been treated with denecimig in earlier studies. This interim analysis focused on patients who moved into the study's Arm 1 and received denecimig once every two weeks for 26 weeks, using a dosing schedule tiered by body weight. NCT05685238+1A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia ANCT05685238Denecimig (Mim8) prophylaxis once-every-2-weeks for hemophilia A with or without inhibitors - 26-week results from FRONTIER.Jul 17, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
How it was done
Thirty-seven patients aged 12 and older, all of whom had prior exposure to denecimig for a mean of 1.73 years in an earlier Phase 2 study, entered the every-2-week arm and were followed for 26 weeks. The primary endpoint was the number of treatment-emergent adverse events; secondary measures included injection-site reactions, anti-denecimig antibody formation, plasma drug concentrations, and treated bleeding episodes. DenecimigDenecimig (Mim8) prophylaxis once-every-2-weeks for hemophilia A with or without inhibitors - 26-week results from FRONTIER.Jul 17, 2026
The result
Sixty treatment-emergent adverse events occurred across 20 of the 37 patients. Most were mild or moderate (98.3%), judged unlikely to be related to denecimig (75.0%), and had resolved by the time of the analysis (90.0%). No adverse event led to stopping treatment, and none were fatal. Two patients accounted for 14 injection-site reactions, and plasma concentrations of denecimig stayed stable through week 26. DenecimigDenecimig (Mim8) prophylaxis once-every-2-weeks for hemophilia A with or without inhibitors - 26-week results from FRONTIER.Jul 17, 2026
Bleeding control
The estimated mean annualized bleeding rate was 0.38 bleeds per patient-year, and 83.8% of the 37 patients had zero treated bleeding episodes during the 26-week period. That bleed-control result sits alongside a separately published Phase 3 dataset for denecimig, which reported reduced annualized bleeding versus prior treatment in a NEJM publication, and this interim look extends that profile to a less frequent, every-2-week injection schedule rather than establishing it fresh. DenecimigDenecimig (Mim8) prophylaxis once-every-2-weeks for hemophilia A with or without inhibitors - 26-week results from FRONTIER.Jul 17, 2026
Where it fits
Denecimig acts through the same broad mechanistic idea as Roche's emicizumab, a bispecific antibody that mimics factor VIII activity and is approved for hemophilia A, though the FRONTIER4 dataset itself carries no head-to-head comparator arm. Both denecimig and emicizumab are tested across a small set of trials tied to this target and mechanism, alongside older Factor VIIa-pathway programs from Novo Nordisk in the same congenital hemophilia A population; none of those older programs share denecimig's bispecific-antibody design. NCT05685238A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia ANCT05685238
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.